Columbia, MD – A pilot survey conducted by Ipsos Healthcare in February, 2013 in the US, 5-EU (UK, Germany, France, Italy, Spain), Brazil and China revealed that 40% of oncologists (range: 36% (Brazil) – 44% (China)) across the surveyed geographies are not sure whether their ‘local healthcare reforms are heading in the right direction’.
Two hundred and fifty seven oncologists (medical oncologists: 69%) were randomly sampled across the selected geographies to participate in a pilot cross-sectional survey assessing their perceptions of healthcare reforms in their respective countries, and their consideration of the following, when prescribing oncology medications: ‘real-world evidence’ on product effectiveness and safety, patient quality of life (QoL) and patient affordability and product cost.
“In an effort to improve patient access to healthcare and medicines, significant healthcare reforms are underway across the globe,” says Siva Narayanan, who leads the Evidence Generation, Value and Access Center of Excellence at Ipsos Healthcare. “A commonality in healthcare reforms across these countries includes an emphasis on real-world evidence, specifically, comparative effectiveness of standard of care medications. The goal is to drive appropriate therapeutic choice, with an increased push towards the use of low-cost medications, and an increased focus on strengthening the standard of care and access to care.”
“In the Ipsos survey, a majority of the oncologists across the markets studied indicated that they consider ‘all the time’ or ‘most of the time’ the ‘real-world evidence’ on product safety and effectiveness (mean: 87%; range: 84% (5-EU) - 92% (Brazil)), patient ‘quality of life’ (mean: 94%; range: 88% (China)-96% (5-EU)), and patient affordability and product cost (mean: 65%; range: 50% (5-EU) - 91% (China)) when they prescribe medications to their patients. These varied across the surveyed regions.
There were also differences in oncologist perceptions toward the implications of local healthcare reform on them and their practices, with the percentage reporting concerns about the impact of healthcare reform on them and their practice varying between the countries (mean: 38%; range: 50% (US) - 19% (Brazil)).
“Reimbursement rates for products and services are under scrutiny and risk sharing agreements between several stakeholders in the healthcare systems are being explored, putting pressure on product manufacturers as well as physicians. Healthcare funding cuts at regional or national levels further puts increased pressure on these stakeholders. This backdrop could have influenced the oncologists’ perceptions observed in our pilot survey,” Narayanan concludes. “We are just scratching the surface, with this pilot survey; we intend to undertake evaluations of healthcare stakeholder dynamics, with a specific focus on the 4Ps – namely, the Patients, Physicians, Payers and Policy Makers – with the goal of devising optimal evidence generation and market access strategies for our clients.”
For more information on this news release please contact:
Senior Vice President
Evidence Generation, Value and Access Center of Excellence
About Ipsos Healthcare’s Evidence Generation, Value and Access Portfolio
Ipsos Healthcare’s Evidence Generation, Value and Access Portfolio focuses on providing insights into payer, physician and patient needs and market barriers - and, accordingly, generates or demonstrates clinical, economic and humanistic value propositions of products and services for optimal market access across the market segments and therapy areas. The portfolio’s capabilities include traditional secondary research, retrospective and prospective observational cohort studies, cross-sectional surveys, and quantitative/qualitative research in the market access arena, leveraging our access to patients, physicians and payer stakeholders globally.
About Ipsos Healthcare’s Global Oncology Portfolio
Ipsos Healthcare’s Global Oncology Portfolio spans both syndicated and custom research, with the ability to combine the two approaches for deeper insights. Syndicated oncology services include the market-leading Global Oncology Monitor – which offers data on all key patient & treatment metrics across the Americas, Europe, Asia Pacific and Japan – alongside newer services including molecular diagnostics, social listening and a suite of commercial strategy offerings. The portfolio’s custom capabilities include pre- and post-launch qualitative and quantitative research, forecasting, data analyses and oncology consulting. Fluency in this highly complex disease area ensures that research findings become actionable recommendations.
About Ipsos Healthcare
Ipsos Healthcare is a global specialised practice focusing on research in the pharmaceutical, bio-tech and medical device markets. It is also a leading provider of global syndicated patient chart studies in 35 markets. Operating in over 40 countries, the team of 500 healthcare market research experts, marketers and client-side brand-builders focuses on delivering outcome-oriented research for its clients. Drawing from a broad range of qualitative and quantitative techniques, Ipsos Healthcare offers custom and syndicated research programs to evaluate the motivations, experiences, interactions and influences of stakeholders forming the multi-customer markets that increasingly drive business success in the healthcare industry.
Ipsos is an independent market research company controlled and managed by research professionals. Founded in France in 1975, Ipsos has grown into a worldwide research group with a strong presence in all key markets. In October 2011 Ipsos completed the acquisition of Synovate. The combination forms the world’s third largest market research company. With offices in 85 countries, Ipsos delivers insightful expertise across six research specializations: advertising, customer loyalty, marketing, media, public affairs research, and survey management.
Ipsos researchers assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience responses to various media and they measure public opinion around the globe.
Ipsos has been listed on the Paris Stock Exchange since 1999 and generated global revenues of €1,789 billion (2.300 billion USD) in 2012.
Visit www.ipsos.com to learn more about Ipsos’ offerings and capabilities.